Trial Profile

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST: INTENSIFY ALL).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms BOOST; BOOST-INTENSIFY-ALL
Sponsors Novo Nordisk

Most Recent Events

01 Dec 2016 Results of pooled data of cost-effectiveness analysis from two phase III studies (BOOST-INTENSIFY-ALL and BOOST-INTENSIFY-PREMIX-1) published in the Diabetes Therapy
26 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
26 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com